Dr. Holger Reithinger, Partner
Dr. Holger Reithinger joined GLSV in October 2004 as Principal in our Munich office. He has over 7 years of venture capital experience in the biotechnology industry. Before joining GLSV, Holger was a Director at 3i Germany’s healthcare practice, where he specialized in early- to mid-stage healthcare investments across Europe. For three years prior to joining 3i, he was an Investment Manager at Technologieholding VC GmbH, which at the time was a leading German specialist fund for early-stage technologies. Technologieholding was acquired by the 3i Group in 2000. Before becoming a venture capitalist, Holger worked in industry as a product development manager at Biometra/Whatman Plc, where he was responsible for the identification, development and marketing of new molecular biology products. Holger has served on the boards of several early-stage life science companies including Epigenomics AG (IPO 2004), MBT AG (assets sold to Medigene AG), 4SC AG (IPO 2005), Fibrex Medical Inc., NeuraXo Biotech GmbH and others. He holds a PhD in Biochemistry, which he obtained on protein design in the department of Prof. Dr. Hartmut Michel (Nobel Laureate 1988)1 at the University of Frankfurt / Max-Planck-Institute of Biophysics. As an undergraduate, he studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich.
< back